Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis: Oxaliplatin in neoadjuvant treatment for rectal cancer

BACKGROUND: Neoadjuvant fluoropirimidine (5FU)-based chemoradiotherapy (CRT) has been considered the standard of care for locally advanced rectal cancer (LARC). Whether addition of oxaliplatin (OXP) will further improve clinical outcomes is still debated. We conducted a meta-analysis to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: De Felice, Francesca, Benevento, Ilaria, Magnante, Anna Lisa, Musio, Daniela, Bulzonetti, Nadia, Caiazzo, Rossella, Tombolini, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427623/
https://www.ncbi.nlm.nih.gov/pubmed/28499428
http://dx.doi.org/10.1186/s12885-017-3323-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427623/
https://www.ncbi.nlm.nih.gov/pubmed/28499428
http://dx.doi.org/10.1186/s12885-017-3323-4

Ejemplares similares